Selecta To Perform Preclinical Malaria Vaccine Work For SAIC
This article was originally published in The Pink Sheet Daily
Biotech will combine its SVP platform technology with a SAIC-developed antigen to try to find the key to treating malaria.
You may also be interested in...
European economists meeting in London discuss drug innovation’s costs to the larger health system, research funding sources, and “sin taxes.”
Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.
The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms.